Property | Value |
?:abstract
|
-
Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia. In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR. We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p = 0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1016/j.mad.2020.111413
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/b855432c1d08eecf934f465a75f564bc880fff10.json; document_parses/pdf_json/ceb6aac829e9a86040566f82d8d3323c75ccdc14.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7722494.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Decreased serum levels of the inflammaging marker miR-146a are associated with non-clinical response to tocilizumab in COVID-19 patients
|
?:type
|
|
?:year
|
|